Study of adebrelimab, nab-paclitaxel, and nedaplatin before surgery for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of immunotherapy (adebrelimab) and two chemotherapy drugs before surgery for patients with advanced but removable esophageal cancer. The goal is to see if this treatment shrinks the tumor and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of esophageal cancer called squamous cell carcinoma that can be removed with surgery.
- Your cancer is locally advanced (stage II to III) and has not spread to distant organs.
- You have not had any previous treatment for this cancer.
- You are in good general health, able to do daily activities (ECOG 0 or 1).
- Your heart, liver, kidneys, and blood counts are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called Adebrelimab combined with chemotherapy before surgery for esophageal cancer. It aims to shrink the tumor and make it easier to remove completely.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy, given before surgery, helps shrink esophageal cancer tumors and improves outcomes. It is for people with a specific type of esophageal cancer that has not spread widely.
This trial tests a treatment given before surgery for patients with a type of esophageal cancer called squamous cell carcinoma, stages II to IVA. The goal is to see if this approach can improve outcomes.
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy before surgery for esophageal cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of the immunotherapy drug adebrelimab (SHR-1316) and chemotherapy given before and after surgery for locally advanced esophageal squamous cell carcinoma that can be removed. The goal is to see if this approach helps shrink the tumor and improves outcomes.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.